Abstract
(Abstracted from J Clin Oncol 2023;41(13):2436–2445 Approximately 80% of patients with ovarian cancer experience recurrence after platinum-based chemotherapy, and unfortunately nearly all will eventually develop platinum-resistant ovarian cancer (PROC). Treatment in this setting consists of nonplatinum chemotherapy with or without bevacizumab; however, each successive line of therapy in PROC is associated with progressively lower response rates.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
